138 related articles for article (PubMed ID: 24312836)
21. The selective 5-HT(1A) receptor antagonist WAY-100635 increases neuronal activity of the basolateral nucleus of the amygdala in 6-hydroxydopamine-lesioned rats.
Zhang QJ; Wu ZH; Liu J; Wang T; Wang S; Han LN
Sheng Li Xue Bao; 2008 Apr; 60(2):259-69. PubMed ID: 18425316
[TBL] [Abstract][Full Text] [Related]
22. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
Prinssen EP; Colpaert FC; Koek W
Eur J Pharmacol; 2002 Oct; 453(2-3):217-21. PubMed ID: 12398907
[TBL] [Abstract][Full Text] [Related]
23. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
24. [Effects of chronic fluoxetine treatment on catalepsy and immune response in mice genetically predisposed to freezing reaction: the role of 5-HT1A and 5-HT2A receptors and tph2 and SERT genes].
Tikhonova MA; Al'perina EL; Tolstikova TG; Bazovkina DV; Di VIu; Idova GV; Kulikov AV; Popova NK
Zh Vyssh Nerv Deiat Im I P Pavlova; 2009; 59(2):237-44. PubMed ID: 19445393
[TBL] [Abstract][Full Text] [Related]
25. The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson's disease.
Wąsik A; Polak D; Romańska I; Michaluk J; Antkiewicz-Michaluk L
Pharmacol Rep; 2016 Dec; 68(6):1205-1213. PubMed ID: 27657483
[TBL] [Abstract][Full Text] [Related]
26. Behavioural effects of serotonin agonists and antagonists in the rat and marmoset.
Elliott PJ; Walsh DM; Close SP; Higgins GA; Hayes AG
Neuropharmacology; 1990 Oct; 29(10):949-56. PubMed ID: 2123971
[TBL] [Abstract][Full Text] [Related]
27. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
28. Brain sites mediating cyclosomatostatin-induced catalepsy in Wistar rats: A specific role for the nigrostriatal system and locus coeruleus.
Ionov ID; Pushinskaya II; Roslavtseva LA; Severtsev NN
Brain Res; 2018 Jul; 1691():26-33. PubMed ID: 29680272
[TBL] [Abstract][Full Text] [Related]
29. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Lin L; Yan M; Wu B; Lin R; Zheng Z
Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
[TBL] [Abstract][Full Text] [Related]
30. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.
Moghaddam HF; Khodayar MJ; Abarghouei SM; Ardestani MS
Saudi Pharm J; 2010 Oct; 18(4):207-15. PubMed ID: 23960729
[TBL] [Abstract][Full Text] [Related]
33. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
Silva C; Fuxe K; Chadi G
J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
[TBL] [Abstract][Full Text] [Related]
34. Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration.
Ushijima I; Mizuki Y; Suetsugi M; Akimoto T; Yamada M
Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):709-21. PubMed ID: 9682282
[TBL] [Abstract][Full Text] [Related]
35. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
36. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model.
Baluchnejadmojarad T; Roghani M; Nadoushan MR; Bagheri M
Phytother Res; 2009 Jan; 23(1):132-5. PubMed ID: 18693302
[TBL] [Abstract][Full Text] [Related]
38. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
Eyvari Brooshghalan S; Sabahi M; Ebadi SA; Sadeghian Z; Mohajjel Nayebi A; Haddadi R
Eur J Pharmacol; 2023 Feb; 941():175517. PubMed ID: 36669615
[TBL] [Abstract][Full Text] [Related]
39. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
[TBL] [Abstract][Full Text] [Related]
40. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
